Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Jean-Philippe Arseneau · Chief of Staff, Finance Canada (FIN)
Varun Srivatsan · Director of Policy, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
Greg Reade · Assistant Secretary to the Cabinet for Economic and Regional Development, Privy Council Office (PCO)
Olesia Bissett · Analyst, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Kaili Levesque · ADM, ISED Deputy to Secretary of State, Innovation, Science and Economic Development Canada (ISED)
Stephanie Tanton · Assistance Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
Olesia Bissett · Analyst, Privy Council Office (PCO)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
David Bredin · Director of Parliamentary Affairs, House of Commons
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Mark Carney · Prime Minister, Prime Minister's Office (PMO)
Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
Yash Nanda · Policy Advisor, Prime Minister's Office (PMO)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Greg Reade · Assistant Secretary to the Cabinet for Economic and Regional Development, Privy Council Office (PCO)
Sachelle Magloire-Prosper · Director of Operations, Privy Council Office (PCO)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Samir Khan · Associate Executive Director, Health Canada (HC)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Arianne Reza · Deputy Minister, Public Services and Procurement Canada (PSPC)
Joelle Paquette · Associate Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Ethan Bubba · Parliamentary Assistant, House of Commons
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Janice Charette · Chief Trade Negotiator to the US, Global Affairs Canada (GAC)
Martin Moen · Associate Assistant Deputy Minister, Global Affairs Canada (GAC)
Rodrigo Arancibia · Director General, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Sara O'Connor · AADM, Regulatory Operations and Enforcement Brach, Health Canada (HC)
Celia Lourenco · AADM, Health Products and Food Branch, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Justine Frame · Policy Advisor, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.